MFNG is an independent prognostic marker for osteosarcoma.
Fringe
MFNG
Osteosarcoma
Prognosis
Recurrence
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
26 Jul 2023
26 Jul 2023
Historique:
received:
07
07
2022
accepted:
13
05
2023
medline:
28
7
2023
pubmed:
27
7
2023
entrez:
26
7
2023
Statut:
epublish
Résumé
Osteosarcoma (OS) has been the most common malignancy of the bone in children and adolescents, and the unsatisfactory prognosis of OS sufferers has long been a hard nut. Here, we delved into the markers with a prognostic value for predicting the prognosis of OS patients. The messenger RNA (mRNA) sequencing data and clinical data of OS were retrieved from a Gene Expression Omnibus (GEO) dataset (GSE39058). Next, prognosis-related genes (PRGs) were filtered with the aid of Kaplan-Meier (K-M) curves and Cox regression analysis (CRA). Later, Gene Ontology (GO) biological process analysis was used in verifying the function of different genes. CCK-8 and cell apoptosis assay were performed to evaluate the function of MFNG in U2OS cells. Among the obtained genes, Manic Fringe (MFNG) had the closest relevance to prognosis and clinical traits, thus becoming the research object herein. In light of the expression level of MFNG, patients fell into high- and low-MFNG groups. Patients with elevated MFNG expression had a worse prognosis, according to the survival analysis. It was unveiled by the univariate and multivariate analyses that MFNG expression was an independent adverse prognostic factor for disease-free survival in OS patients (p = 0.006). Meanwhile, MFNG expression was linked to gender and tumor recurrence, and it was higher in patients with OS recurrence. Moreover, overexpression of MFNG promoted the cell proliferation and inhibited the cell apoptosis of U2OS cells. The expression level of MFNG negatively correlated with OS progression, and as an independent adverse prognostic factor for disease-free survival in OS patients. Moreover, MFNG regulated the cell proliferation and apoptosis of OS cells.
Sections du résumé
BACKGROUND
BACKGROUND
Osteosarcoma (OS) has been the most common malignancy of the bone in children and adolescents, and the unsatisfactory prognosis of OS sufferers has long been a hard nut. Here, we delved into the markers with a prognostic value for predicting the prognosis of OS patients.
METHODS
METHODS
The messenger RNA (mRNA) sequencing data and clinical data of OS were retrieved from a Gene Expression Omnibus (GEO) dataset (GSE39058). Next, prognosis-related genes (PRGs) were filtered with the aid of Kaplan-Meier (K-M) curves and Cox regression analysis (CRA). Later, Gene Ontology (GO) biological process analysis was used in verifying the function of different genes. CCK-8 and cell apoptosis assay were performed to evaluate the function of MFNG in U2OS cells.
RESULTS
RESULTS
Among the obtained genes, Manic Fringe (MFNG) had the closest relevance to prognosis and clinical traits, thus becoming the research object herein. In light of the expression level of MFNG, patients fell into high- and low-MFNG groups. Patients with elevated MFNG expression had a worse prognosis, according to the survival analysis. It was unveiled by the univariate and multivariate analyses that MFNG expression was an independent adverse prognostic factor for disease-free survival in OS patients (p = 0.006). Meanwhile, MFNG expression was linked to gender and tumor recurrence, and it was higher in patients with OS recurrence. Moreover, overexpression of MFNG promoted the cell proliferation and inhibited the cell apoptosis of U2OS cells.
CONCLUSIONS
CONCLUSIONS
The expression level of MFNG negatively correlated with OS progression, and as an independent adverse prognostic factor for disease-free survival in OS patients. Moreover, MFNG regulated the cell proliferation and apoptosis of OS cells.
Identifiants
pubmed: 37496053
doi: 10.1186/s40001-023-01139-x
pii: 10.1186/s40001-023-01139-x
pmc: PMC10369729
doi:
Substances chimiques
MFNG protein, human
EC 2.4.1.222
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
256Informations de copyright
© 2023. The Author(s).
Références
J Cell Sci. 2014 Mar 1;127(Pt 5):923-8
pubmed: 24587488
Eur J Pharmacol. 2021 May 15;899:174058
pubmed: 33757752
Int J Mol Sci. 2022 Mar 19;23(6):
pubmed: 35328752
Biomed Pharmacother. 2022 Jun;150:112993
pubmed: 35462337
Sci Rep. 2021 Nov 22;11(1):22723
pubmed: 34811459
Reprod Sci. 2021 Oct;28(10):2770-2778
pubmed: 34008156
Tissue Cell. 2022 Jun;76:101794
pubmed: 35413492
Invest New Drugs. 2022 Jun;40(3):668-675
pubmed: 35312944
Int J Biol Macromol. 2020 Dec 1;164:456-467
pubmed: 32693135
J Immunol Res. 2022 May 5;2022:3655908
pubmed: 35578666
Cytotherapy. 2022 Jun;24(6):567-576
pubmed: 35193828
Int J Cancer. 2018 Apr 15;142(8):1594-1601
pubmed: 29210060
Chem Biol Interact. 2022 Jun 1;360:109903
pubmed: 35307379
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409176
Mol Ther Nucleic Acids. 2020 Mar 6;19:1470-1481
pubmed: 32160715
Am J Cancer Res. 2021 Jun 15;11(6):3354-3374
pubmed: 34249467
Cancer Res. 2015 May 15;75(10):1936-43
pubmed: 25808869
Biomolecules. 2020 Feb 19;10(2):
pubmed: 32092942
Bioengineered. 2022 Apr;13(4):8087-8100
pubmed: 35294319
PLoS One. 2012;7(10):e47288
pubmed: 23071776
Am J Transl Res. 2022 Feb 15;14(2):752-771
pubmed: 35273683
J Bone Miner Res. 2019 Oct;34(10):1780-1788
pubmed: 31441962
Biosci Rep. 2018 Dec 14;38(6):
pubmed: 30442873
Molecules. 2021 Sep 30;26(19):
pubmed: 34641486
J Cell Physiol. 2018 Nov;233(11):8639-8647
pubmed: 29904919
Acta Biochim Biophys Sin (Shanghai). 2021 May 21;53(6):663-672
pubmed: 33787845
Cancer. 2022 Jun 1;128(11):2107-2118
pubmed: 35226758
J Clin Oncol. 2018 Jan 10;36(2):188-193
pubmed: 29220289
J Bone Miner Res. 2022 May;37(5):885-895
pubmed: 35279875
J Immunol. 2016 Jan 1;196(1):232-43
pubmed: 26608918
Oncol Lett. 2015 Sep;10(3):1704-1708
pubmed: 26622736
Cancer Lett. 2022 Jun 28;536:215660
pubmed: 35318116
Expert Opin Ther Targets. 2013 Aug;17(8):921-36
pubmed: 23755894
Aging (Albany NY). 2020 Dec 19;13(2):2668-2680
pubmed: 33411691
Eur J Cancer. 2019 Mar;109:36-50
pubmed: 30685685
J Biomed Mater Res A. 2020 May;108(5):1035-1044
pubmed: 31925903
Int Immunopharmacol. 2021 Oct;99:107938
pubmed: 34371331
Adv Exp Med Biol. 2020;1258:21-36
pubmed: 32767232
Front Oncol. 2021 Apr 23;11:630706
pubmed: 33968730
Microvasc Res. 2022 Jul;142:104341
pubmed: 35157839
Nat Genet. 1997 Dec;17(4):495-7
pubmed: 9398859
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Orthop Surg. 2022 Jun;14(6):1161-1166
pubmed: 35538733